Thursday, October 13, 2016

BRIEF-Oncogenex says phase 3 ENSPIRIT trial of custirsen in non-small cell lung cancer did not meet primary endpoint

… of custirsen in non-small cell lung cancer
* Oncogenex Pharmaceuticals Inc - trial …
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)